The Future of Insulin Glargine Biosimilars: Key Insights for 2024
Insulin glargine, a long-acting insulin analog, is a cornerstone in diabetes management, providing consistent glucose control over 24 hours. With the global prevalence of diabetes on the rise, insulin glargine biosimilars offer an affordable alternative to branded products like Sanofi’s Lantus